https://newsletter.po.creamermedia.com
Deepening Democracy through Access to Information
Home / News / South African News RSS ← Back
Health|Products
Health|Products
health|products
Close

Email this article

separate emails by commas, maximum limit of 4 addresses

Sponsored by

Close

Article Enquiry

Sahpra registers medicine to treat Covid-19


Close

Sahpra registers medicine to treat Covid-19

Should you have feedback on this article, please complete the fields below.

Please indicate if your feedback is in the form of a letter to the editor that you wish to have published. If so, please be aware that we require that you keep your feedback to below 300 words and we will consider its publication online or in Creamer Media’s print publications, at Creamer Media’s discretion.

We also welcome factual corrections and tip-offs and will protect the identity of our sources, please indicate if this is your wish in your feedback below.


Close

Embed Video

Sahpra registers medicine to treat Covid-19

South African Health Products Regulatory Authority CEO Dr Boitumelo Semete-Makokotlela
South African Health Products Regulatory Authority CEO Dr Boitumelo Semete-Makokotlela

31st January 2023

By: Thabi Shomolekae
Creamer Media Senior Writer

ARTICLE ENQUIRY      SAVE THIS ARTICLE      EMAIL THIS ARTICLE

Font size: -+

South African Health Products Regulatory Authority (Sahpra) CEO Dr Boitumelo Semete-Makokotlela indicated that as Covid-19 is a looming threat, the Sahpra has registered Paxlovid as a treatment.

Paxlovid an anti-viral medicine manufactured by Pfizer that treats mild to moderate Covid-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe Covid-19.

Advertisement

Paxlovid is a 5-day tablet treatment with morning and evening doses.

Its side-effects include hypersensitivity reactions, diarrhoea, vomiting, and altered taste.

Advertisement

Semete-Makokotlela explained that Sahpra is committed to fast-tracking the registration of all health products that are of an urgent nature such as HIV-Aids, cancer and Covid-19.

EMAIL THIS ARTICLE      SAVE THIS ARTICLE      ARTICLE ENQUIRY      FEEDBACK

To subscribe email subscriptions@creamermedia.co.za or click here
To advertise email advertising@creamermedia.co.za or click here


About

Polity.org.za is a product of Creamer Media.
www.creamermedia.co.za

Other Creamer Media Products include:
Engineering News
Mining Weekly
Research Channel Africa

Read more

Subscriptions

We offer a variety of subscriptions to our Magazine, Website, PDF Reports and our photo library.

Subscriptions are available via the Creamer Media Store.

View store

Advertise

Advertising on Polity.org.za is an effective way to build and consolidate a company's profile among clients and prospective clients. Email advertising@creamermedia.co.za

View options

Email Registration Success

Thank you, you have successfully subscribed to one or more of Creamer Media’s email newsletters. You should start receiving the email newsletters in due course.

Our email newsletters may land in your junk or spam folder. To prevent this, kindly add newsletters@creamermedia.co.za to your address book or safe sender list. If you experience any issues with the receipt of our email newsletters, please email subscriptions@creamermedia.co.za